U.S. markets close in 1 hour 25 minutes
  • S&P 500

    3,957.55
    -13.54 (-0.34%)
     
  • Dow 30

    33,080.37
    -91.00 (-0.27%)
     
  • Nasdaq

    13,026.04
    -33.60 (-0.26%)
     
  • Russell 2000

    2,188.58
    +29.90 (+1.39%)
     
  • Crude Oil

    60.58
    -0.98 (-1.59%)
     
  • Gold

    1,683.70
    -30.90 (-1.80%)
     
  • Silver

    24.05
    -0.73 (-2.93%)
     
  • EUR/USD

    1.1722
    -0.0050 (-0.42%)
     
  • 10-Yr Bond

    1.7240
    +0.0030 (+0.17%)
     
  • GBP/USD

    1.3717
    -0.0047 (-0.34%)
     
  • USD/JPY

    110.3420
    +0.5340 (+0.49%)
     
  • BTC-USD

    59,034.46
    +1,037.75 (+1.79%)
     
  • CMC Crypto 200

    1,187.52
    +34.03 (+2.95%)
     
  • FTSE 100

    6,772.12
    +35.95 (+0.53%)
     
  • Nikkei 225

    29,432.70
    +48.18 (+0.16%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BLU, EBIX and VRM

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / March 30, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

BELLUS Health Inc. (NASDAQ: BLU)
Class Period: September 5, 2019 - July 5, 2020
Lead Plaintiff Deadline: May 17, 2021

During the class period, BELLUS Health Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: while BLU-5937's "high selectivity" contributed to the drug causing little to no taste alteration in chronic cough patients, that high selectivity also contributed to the drug potentially being less efficacious and thus likely not be able to meet the primary endpoint of the Company's Phase 2 trial.

Learn about your recoverable losses in BLU: http://www.kleinstocklaw.com/pslra-1/bellus-health-inc-loss-submission-form?id=14229&from=1

Ebix, Inc. (NASDAQ: EBIX)
Class Period: November 9, 2020 - February 19, 2021
Lead Plaintiff Deadline: April 23, 2021

The complaint alleges that during the class period Ebix, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) there was insufficient audit evidence to determine the business purpose of certain significant unusual transactions in Ebix's gift card business in India during the fourth quarter of 2020; (2) there was a material weakness in Company's internal controls over the gift or prepaid revenue transaction cycle; and (3) the Company's independent auditor was reasonably likely to resign over disagreements with Ebix regarding $30 million that had been transferred into a commingled trust account of Ebix's outside legal counsel; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in EBIX: http://www.kleinstocklaw.com/pslra-1/ebix-inc-loss-submission-form?id=14229&from=1

Vroom, Inc. (NASDAQ: VRM)
Class Period: June 9, 2020 - March 3, 2021
Lead Plaintiff Deadline: May 21, 2021

The complaint alleges that throughout the class period Vroom, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Vroom had not demonstrated that it was able to control and scale growth in respect to its salesforce to meet the demand for its products; (2) as a result, the Company was forced to discount aged inventory to move through its retail channels or liquidated in its wholesale channels; (3) as a result, the ecommerce gross profit per unit was reasonably likely to decline; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in VRM: http://www.kleinstocklaw.com/pslra-1/vroom-inc-loss-submission-form?id=14229&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/638215/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-BLU-EBIX-and-VRM